文献速递肾小球疾病

泰它西普靶向Gd-IgA1与自身抗体生成B细胞治疗IgA肾病

Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本文综述了靶向Gd-IgA1生成细胞治疗IgA肾病的进展,重点讨论BAFF/APRIL抑制剂泰它西普。泰它西普双靶向BAFF和APRIL,抑制Gd-IgA1及其自身抗体产生。3期试验A阶段显示,泰它西普组第39周24小时尿蛋白肌酐比降低55%,eGFR稳定,耐受性和安全性良好。

要点

  • 泰它西普双靶向BAFF和APRIL,抑制Gd-IgA1及其自身抗体产生。
  • 3期试验A阶段:泰它西普组第39周24h UPCR降低55%,eGFR稳定。
  • 泰它西普耐受性和安全性良好。

核心结论

  • 泰它西普通过双靶向BAFF和APRIL抑制Gd-IgA1及其自身抗体产生,在IgA肾病治疗中显示治疗潜力。

研究设计与样本

  • 综述总结靶向Gd-IgA1生成细胞治疗IgA肾病的进展,重点讨论BAFF/APRIL抑制剂等策略。

主要发现

  • 3期临床试验A阶段结果显示,泰它西普组第39周24小时尿蛋白肌酐比降低55%,eGFR稳定,耐受性和安全性良好。

关键数值与推荐

  • 泰它西普组第39周24小时尿蛋白肌酐比降低55%,eGFR稳定(对比安慰剂组)。

临床怎么用

  • 泰它西普可作为靶向Gd-IgA1及其自身抗体生成的疾病修饰治疗选择,尤其适用于早期IgA肾病患者以阻止不可逆肾损伤。

局限性

  • 综述指出优化这些干预措施仍面临主要挑战,并提出了未来研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis and a leading cause of end-stage renal disease for young adults. The key pathogenesis of IgAN involves overproduction of galactose-deficient IgA1 (Gd-IgA1) and anti-Gd-IgA1 antibodies, resulting in formation of circulating immune complexes that deposit in the glomerular mesangium. Consequently, emerging therapeutic strategies for IgAN aim to target and reduce aberrant Gd-IgA1 and its associated immune complexes. This disease-modifying approach confers benefits across multiple stages of IgAN progression, particularly in the early phase to halt irreversible renal damage. B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) are critical cytokines that promote the differentiation, development and activation of B cells and plasma cells. Telitacicept, a novel recombinant fusion protein that dual-targets BAFF and APRIL, exhibits considerable therapeutic potential by inhibiting the production of Gd-IgA1 and its autoantibodies. Stage A results of the Phase 3 clinical trial demonstrated that patients in the telitacicept group achieved a 55% reduction in 24-h urinary protein-to-creatinine ratio and stable estimated glomerular filtration rate at Week 39 versus the placebo group, with favorable tolerability and safety. This review summarizes current progresses in targeting Gd-IgA1-producing cells for the treatment of IgAN, with a focus on therapeutic strategies including BAFF/APRIL inhibitors. Furthermore, it delineates the major challenges and future research directions aimed at optimizing these interventions.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Weng Q, Zhu X, Ren H, et al. Telitacicept targets Gd-IgA1 and autoantibody-producing B cells in IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 41524180. doi:10.1093/ndt/gfag001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。